Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Patent
1994-07-22
1997-02-18
Gitomer, Ralph J.
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
514296, 546 98, C12Q 168, A61K 3144
Patent
active
056040954
ABSTRACT:
The present invention provides novel bis-naphthalimides characterized by having a linker containing a heteroatom, their preparation, pharmaceutical compositions thereof, and various methods of using the bis-naphthalimides. Particularly preferred bis-naphthalimides have a linker of about 8-16 atoms where the heteroatom is oxygen, sulfur, sulfur oxide or sulfur dioxide. The bis-naphthalimides provided herein have exceptional DNA binding properties and demonstrate cytotoxicity in both in vitro and in vivo tumor models, in particular, against melanoma.
REFERENCES:
patent: 4841052 (1989-06-01), Harnisch et al.
patent: 4874863 (1989-10-01), Brana et al.
patent: 5086059 (1992-02-01), Ardecky et al.
patent: 5206249 (1993-04-01), Sun
patent: 5206250 (1993-04-01), Sun
patent: 5235045 (1993-08-01), Lewis et al.
patent: 5376664 (1994-12-01), Kaltenbach
Stafford et al., "DNA binding characteristics of DMP 840, a novel bis-naphthalimide anti-tumor agent," Proc. Amer. Assoc. Cancer Res., 34:384. Abstract 2292, 1993.
Sun et al., "Synthesis and anti-proliferative properties of novel bis-naphthalimides, CMP 840 and its stereoisomers," Proc. Amer. Assoc. Cancer Res., 34:384. Abstract 2287, 1993.
Talbot et al., "Anthrapyrazole CI941: A Highly Active New Agent in the Treatment of Advanced Breast Cancer," J. Clin. Oncol., 9:2141-2147, 1991.
Cornbleet et al., "Mitoxantrone for the Treatment of Advanced Breast Cancer: Single-agent Therapy in Previously Untreated Patients," Eur. J. Cancer Clin. Oncol., 20:1141-1146, 1984.
Czerniak et al., "Mangitude and duration of anti-tumor response caused by DMP 840, a novel bis-naphthalimide anti-tumor agent, against human solid tumor xenografts in vivo," Proc. Amer. Assoc. Cancer Res., 34:384. Abstract 2289, 1993.
Hsiang et al., "Topoisomerase II-Mediated DNA Cleavage by Amonafide and Its Structural Analogs," Molec. Pharmcol., 36:371-376, 1989.
McRipley et al., "Evaluation of DMP 840, a novel anti-tumor agent, in murine and human tumor models in vivo," Proc. Amer. Assoc. Cancer Res., 34:384. Abstract 2291, 1993.
Papp et al., "Mechanistic and anti-proliferative activities of DMP 840, a novel bis-naphthalimide anti-tumor agent," Proc. Amer. Assoc. Cancer Res., 34:384. Abstract 2288, 1993.
Qian et al., "Bis-naphthalimides bind strongly to DNA and inhibit topoisomerase II but do not stabilize topoisomerase II/DNA cleavable complexes," Proc. Amer. Assoc. Cancer, 34:426. Abstract 2542, 1993.
Arthuad et al., "Preclinical toxicity of the anticancer agent DMP 840 in mice, rats and dogs," Proc. Amer. Assoc. Cancer Res., 34;384. Abstract 2290, 1993.
Bousquet et al., "Bis-naphthalimides demonstrate significant antitumor activity in vivo," Proc. Amer. Assoc. Cancer Res., 34:374. Abstract 2230, 1993.
Brana et al., "Bis-naphthalimides, a novel class of antitumor agents," Proc. Amer. Assoc. Cancer Res., 34:383. Abstract 2285, 1993.
Chen et al., "Effects of a bis-naphthalimide anti-cancer agent XB596 on cell cycle kinetics on MCF-7 human breast tumor cells," Proc. Amer. Assoc. Cancer Res., 34:348. Abstract 2074, 1993.
Chen et al., "XB596, a promising bis-naphthalimide anti-cancer agent," Anti-Cancer Drugs, 4:447-457, 1993.
Kirshenbaum M., (R,R)-2,2'-[1,2-ethanediylbis[imino(1-methyl-2,1-ethanediyl)]]-bis[5-nitro -1H-benz[de]isoquinoline-1,3-(2H)-dione] dimethanesulfonate (DMP 840) . . . Cancer Research 54 (1994) pp. 2199-2206.
Berners-Price, "Stereospecific Hydrogen-Bonding in Mononucleotide Adducts of Platinum Anticancer Complexes in Aqueous Solution," J. Am. Chem. Soc., 115:8649-8659, 1993.
Bowler and Lippard, "Modulation of platinum antitumor drug binding to DNA by linked and free intercalators," Biochemistry, 25:3031-3038, 1986.
Denny and Baguley, "Acridine-based anticancer drugs," Molecular Aspects of Anticancer Drug-DNA Interactions, vol. 2, chapter 7 (Neidle and Waring, eds.), CRC Press, Boca Raton, FL, 1994.
Farrell, N., "Nonclassical Platinum Antitumor Agents: Perspectives for Design and Development of New Drugs Complementary to Cisplatin," Cancer Invest., 11(5):578-589, 1993.
Gean et al., "Preparation, characterization and the anticancer activity of a novel series of triaminemonochloroplatinum(II) cations linked to anthraquinone intercalators," Eur. J. Med. Chem., 26:593-598, 1991.
Kraker et al., "Anticancer Activity in Murine and Human Tumor Cell Lines of Bis(platinum) Complexes Incorporating Straight-Chain Aliphatic Diamine Linker Groups," J. Med. Chem., 35:4526-4532, 1992.
Gibson et al., "Preparation, Characterization and Anticancer Activity of a Series of cis-PtCl.sub.2 Complexes Linked to Anthraquinone Intercalators," J. Med. Chem., 34:414-420, 1991.
McKeage and Kelland, "New Platinum Drugs," Molecular Aspects of Anticancer Drug-DNA Interactions, vol. 1, chapter 6 (Neidle and Waring, eds.), CRC Press, Boca Raton, FL, 1993.
Lee et al., "DNA-Directed Alkylating Agents. 5. Acridinecarboxamide Derivatives of (1,2-Diaminoethane)dichloroplatinum(II)," J. Med. Chem., 35:2983-2987, 1992.
Palmer et al., "Synthesis, DNA binding interactions and biological activity of bis-platinum(II) complexes of N,N,N',N'-tetrakis(2-aminoethyl)diamines," Anti-Cancer Drug Design, 7:385-401, 1992.
Roberts et al., "Interaction of novel bis(platinum) complexes with DNA," Nucl. Acids Res., 17(23):9719-9733, 1989.
Sundquist et al., "Synthesis, Characterization and Biological Activity of cis-Diammineplatinum(II) Complexes of the DNA Intercalators 9-Aminoacridine and Chloroquine," J. Am. Chem. Soc., 112:1590-1596, 1990.
Webster et al., "cis-Bis(pyridine)platinum(II) Organoamides with Unexpected Growth Inhibition Properties and Antitumor Activity," J. Med. Chem., 35:3349-3353, 1992.
Woynarowski et al., "Effects on isolated and intracellular DNA of AB018, a novel cytotoxic drug with DNA alkylating, groove binding, and intercalating moieties," Fifth International Congress on Anti-cancer Chemotherapy, Paris, France, Jan. 31-Feb. 3, 1995.
Woynarowski et al., "Effects on isolated and intracellular DNA of AB018, a novel cytotoxic drug with DNA alkylating, groove binding, and intercalating moieties," Abstract for poster presentation for Fifth International Congress on Anti-cancer Chemotherapy, Paris, France, Jan. 31-Feb. 3, 1995.
Yamashita et al., "Cytotoxicity of Platinum (IV) and Platinum(II) Complexes Containing 1R,2R-Cyclohexanediamine as a Ligand," Biol. Pharm. Bull., 16(10):1014-1018, 1993.
Chen Shih-Fong
Dexter Daniel L.
Mittakanti Mallaiah
Reedy Peech S.
Weis Alexander L.
Cancer Therapy & Research Center
Gitomer Ralph J.
LandOfFree
Unsymmetrically linked bisnaphthalimides as antitumor agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Unsymmetrically linked bisnaphthalimides as antitumor agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Unsymmetrically linked bisnaphthalimides as antitumor agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1601817